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Abstract In prelabour rupture of membranes (PROM) or
preterm PROM the amniotic membranes rupture prior to
labour. Where this is not overt a speculum examination is
undertaken to confirm diagnosis. The Vision Amniotic
Leak Detector (ALD) is a panty liner that can diagnose
amniotic fluid as a cause of vaginal wetness. It was eval-
uated by the UK National Institute for Health and Care
Excellence (NICE) as part of the Medical Technologies
Evaluation Programme. The sponsor (CommonSense Ltd)
identified five studies, of which three were deemed within
scope by the External Assessment Centre (EAC). Two of
these three used an inappropriate comparator. The EAC
recalculated the diagnostic accuracy of Vision ALD using
speculum examination as the comparator: sensitivity of
97 % (95 % CI 93–99 %), negative predictive value of
96 % (95 % CI 92–98 %). A negative result would there-
fore allow patients to be discharged with confidence. In the
sponsor’s cost-consequence model only patients with a
positive Vision ALD result would have a speculum
examination, producing a cost saving of around £10 per
patient. The EAC felt that some costs were unjustified and
the model did not include infection outcomes or use in a
community setting. The EAC revised the sponsor’s model
and found the results were most sensitive to clinician costs.
Vision ALD was associated with savings of around £15–
£25 per patient when administration in lower-cost com-
munity healthcare avoided a referral to a higher-cost
secondary-care centre. NICE published guidance MTG15
in July 2013 recommending that the case for adopting
Vision ALD was supported by the evidence.
Key Points for Decision Makers
The available evidence indicates that Vision ALD
has a high sensitivity and a high negative predictive
value. This means that patients can be reliably
discharged with a negative PROM/PPROM
diagnosis if they have a negative Vision ALD result.
The false negative rate of Vision ALD is almost
identical to that of speculum examination
(approximately 3–4 %), so the number of patients
wrongly discharged with PROM/PPROM will be
similar to those with the speculum examination.
Vision ALD can reduce the number of unnecessary
speculum examinations by around 42 %, and it is
also less invasive than the speculum examination,
which may benefit patients.
Referrals to secondary-care clinic may be avoided by
using Vision ALD in the community setting, which
could be cost saving and release clinic resources.
1 Introduction
This is one in a series of articles in Applied Health Eco-
nomics and Health Policy summarising guidance produced
by the National Institute for Health and Care Excellence
(NICE) Medical Technologies Evaluation Programme
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(MTEP) [1–6]. This evaluation programme provides
guidance on medical devices and diagnostic technologies
to the UK National Health Service (NHS) and supports the
adoption of technologies that improve clinical outcomes or
the patient experience and/or that result in cost savings.
The NICE MTEP process is explained by Campbell and
Campbell in the first publication in this Applied Health
Economics and Health Policy series [7]. This article sum-
marises the External Assessment Centre (EAC) report and
Medical Technology Guidance (MTG) for the use of the
Vision Amniotic Leak Detector (ALD) as a diagnostic
tool for vaginal wetness during pregnancy [8].
2 Background
Premature or prelabour rupture of membranes (PROM) is a
condition in which the amniotic membrane ruptures before
the onset of labour and where the pregnancy is 37 weeks’
gestation or more. PROM occurs in 8–10 % of full-term
pregnancies [9, 10] and is followed by labour within 24 h in
60 % of cases [11]. Where this does not happen labour may
be induced, as membrane rupture increases the risk of a
serious neonatal infection from 0.5 to 1 % [11]. If PROM
is diagnosed the woman should be provided with advice
about the risks and options and appropriate clinical moni-
toring should be administered. Preterm PROM (PPROM) is
membrane rupture in pregnancies of less than 37 weeks’
gestation. It affects around 3 % of all pregnancies and
approximately a third of preterm births [9, 10, 12].
Approximately one-third of patients with PPROM have a
positive amniotic fluid culture, indicating infection which
poses a risk to both the woman and the baby [12]. The
NICE clinical guideline for the Induction of Labour states
that induction should not take place in PPROM before
34 weeks unless there are additional obstetric indications.
The decision to induce labour in such cases is influenced by
the gestational age, additional obstetric indications, avail-
ability of neonatal critical care facilities, and the risks to
the mother and neonate [13].
Membrane rupture is often accompanied by a gush of
liquor and the diagnosis is therefore unequivocal. However,
in some cases the presenting symptom may be an unex-
plained increase in vaginal wetness. Alternative causes for
this symptom are leaking urine and vaginal infection, but
these are of lesser clinical urgency. Differential diagnosis of
vaginal wetness in pregnancy is therefore important and the
early detection of leaking amniotic fluid may lead to a
reduction in maternal and neonatal morbidity [14]. In the
NHS currently, diagnosis is based on a sterile speculum
examination inwhich the patient lies supine for up to an hour,
following which a midwife or obstetrician will look for
pooled liquor in the posterior fornix. Additional diagnostic
tests may be used including nitrazine pH, ultrasound exam-
ination of the volume of fluid in the uterus and the fern test
(crystallisation of amniotic fluid on a microscope slide).
However, all of these require a vaginal examination and/or
skilled clinical assessment. Diagnostic accuracy for these
tests are less than ideal with various ranges of values quoted
in the published literature [9, 12, 15, 16].
Amniotic fluid normally has a pH of 6.5 or above
whereas vaginal pH is 3.5–4.5. Vision ALD (Common
Sense Ltd, UK) is a panty-liner with a removable indicator
strip that turns blue-green on contact with fluid with a pH
higher than 5.2. The panty-liner is worn until wet or for up
to 12 h and the indicator strip is removed and placed in a
plastic drying box for 30 min. The colour of the indicator
strip is then assessed. Urine has a pH of 7.0 and will also
change the colour of the indicator strip initially. However,
high concentrations of ammonia, such as in urine, cause the
colour to fade within 30 min. Infection (including bacterial
vaginosis, trichomoniasis or desquamative inflammatory
vaginitis) can also raise vaginal pH and produce a positive
result. Infected vaginal discharge does not contain high
levels of ammonia so the colour change will remain after
30 min. The device is also known as AmnioSense, Al-
Sense, Meitest and Amniscreen.
3 Decision Problem (Scope)
NICE defines the scope of the evaluation prior to the
sponsor’s submission of evidence.
The benefits of Vision ALD to pregnant women claimed
by the sponsor [17] are:
• A reduction in unnecessary speculum examinations.
• A reduction in the time spent in hospital. Women using
Vision ALD will not require a hospital bed and can
undergo the test as an outpatient or in a community
setting; there is no requirement for them to lie down
whilst wearing the liner.
• A reduced risk of infection from speculum examina-
tion, particularly if repeat examinations are required.
• The incidental detection of possible vaginal infection.
The benefits of Vision ALD to the healthcare system
claimed by the sponsor are:
• A reduction in the costs associated with the avoidance
of speculum examination.
• A reduction in staff time and hospital bed use.
3.1 Population
The population of interest was pregnant women with
unidentified vaginal wetness which may be leaking
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amniotic fluid caused by ruptured membranes. The use of
Vision ALD as a screening test in women with a history of
PROM or PPROM and its routine use following amnio-
centesis were excluded.
3.2 Intervention (Vision ALD)
The intervention was Vision ALD administered by a
healthcare professional in a community or acute setting.
The use of Vision ALD by the patient herself was exclu-
ded. In their submission the sponsor (CommonSense Ltd.,
Israel) only included the use of Vision ALD in a hospital
setting in their economic model and did not address its use
in a community setting.
3.3 Comparator (Current Practice)
The comparator was speculum examination alone. In the
NICE clinical guideline for Intrapartum Care [11] a
speculum examination is only required if rupture of the
membranes at term is uncertain. The Royal College of
Obstetricians and Gynaecologists guideline on Preterm
Prelabour Rupture of Membranes [12] recommends the use
of clinical history followed by a sterile speculum exami-
nation. Ultrasound examination is considered useful in
some cases.
Speculum examination may result in a false negative
result if the leak of amniotic fluid is particularly slow or
intermittent or if insufficient time is allowed for pooling. In
their submission the sponsor stated that the speculum
examination has a low sensitivity and quoted false negative
rates of 12–30 %. However, the EAC could only identify
one experimental study evaluating the diagnostic perfor-
mance of speculum examination alone, which reported a
12 % false negative rate [18]. The EAC considered that this
had not been calculated correctly and re-calculated the
false negative rate for speculum examination alone as 3.8
or 3.9 % [19].
3.4 Outcomes
The outcomes specified for consideration in the scope
included incidence of speculum examinations, diagnostic
performance of Vision ALD in the identification of amni-
otic fluid leak, identification of vaginal infection, incidence
of speculum-associated cross-infection, bed utilisation and
staff time, and device-related adverse events. Only inci-
dence of speculum examinations and the diagnostic per-
formance of Vision ALD for rupture of membranes (ROM)
were addressed by the sponsor’s submission. Additional
work by the EAC also addressed the identification of
vaginal infection.
4 Review of Clinical and Economic Evidence
The sponsor provided an evidence submission to NICE that
reviewed the clinical and cost evidence for Vision ALD
and presented a de novo cost-consequences model. Cedar a
collaboration between Cardiff and Vale University Health
Board and Cardiff University, was the EAC commissioned
by NICE to produce the assessment report for this tech-
nology. The role of the EAC is to review and critique the
sponsor’s submission: to ensure completeness and rele-
vance of the evidence presented, to appraise its quality and
to check the interpretation of this evidence with respect to
the scope. The aim is to evaluate whether Vision ALD
carries a diagnostic advantage and/or a reduced cost in
comparison to current NHS standard care. The EAC was
able to call upon clinical experts (research midwives and
obstetricians) where clarification or advice on current UK
practice was required.
4.1 Sponsor’s Submission of Clinical Effectiveness
Evidence
The sponsor presented four studies, one of which was a
laboratory study that assessed the ability of Vision ALD to
detect small amounts of amniotic fluid [20]. The other three
studies were clinical trials of Vision ALD in which diag-
nostic accuracy was assessed against a reference test [21–
23]. The EAC’s literature search and grey literature search
did not identify any studies not included in the sponsor’s
submission. The three clinical studies are summarised in
Table 1. All three studies recruited women who presented
at a labour or antenatal unit in secondary care. Comparative
results were assessed in women presenting with unex-
plained vaginal wetness or a history suggestive of mem-
brane rupture. In Bornstein et al. [21], two additional
groups were recruited: a positive diagnosis group of
women with overt spontaneous or artificial rupture of the
membranes (n = 42) and a negative diagnosis group of
women presenting for routine antenatal checks with no
complaint of vaginal wetness (n = 27).
Only one of the studies (Mulhair et al.) used speculum
examination alone as the comparator, as specified in the
NICE scope. In the other two studies [21, 22] a positive
comparator test was defined as a positive result from either
speculum examination alone, or from both nitrazine pH and
ferning tests.1 In Bornstein et al. [22], the primary outcome
was the comparison between the patient’s reading of the
Vision ALD result and the initial clinical diagnosis. In this
1 The description in Bornstein et al. [21] differs from this description,
but the authors confirmed that the published paper contained a
typographical error and that the reference test in the two papers were
the same.
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study, if the Vision ALD result was positive and the
comparator was negative then the woman was tested for
vaginal infection and underwent a second comparator test
within 48 h.
The results as submitted by the sponsor indicate that
Vision ALD has a high sensitivity ranging from 95.7 to
100.0 % and a reasonably high specificity of 75.0–84.5 %.
(A lower specificity of 65.0 % was reported by Mulhair
et al. [23] but was excluded by the sponsor.) The sponsor
did not report any other outcomes but two studies also
reported positive and negative predictive values:
67.4–87.0 % and 94.7–98.1 %, respectively [22, 23].
Mulhair et al. [23] estimated a 38 % reduction in referrals
to their unit if the device were used in the community and
also carried out a subgroup analysis on preterm subjects:
sensitivity of 93 %, specificity of 76 % (n = 61).
4.2 Critique of Sponsor’s Submission of Clinical
Evidence
The EAC excluded the laboratory study from the analysis
as outside the scope of the evaluation [20]. Each of the
three clinical studies was consistent with the patient pop-
ulation in the NICE scope. Only Mulhair et al. [23] was
also consistent with the scope intervention and comparator.
The interventions varied slightly in the other two studies as
both the patient and one [22] or two [21] investigators
independently read the Vision ALD result. The Bornstein
et al. studies [21, 22] used ‘clinical diagnosis’ as the
comparator so that different reference tests were used for
different patients (differential verification bias). Other
outcomes identified in the scope were not reported: inci-
dence of speculum examinations, speculum cross-infection,
bed utilisation and staff time.
All three of the selected studies classed positive Vision
ALD results due to vaginal infections as false positives,
whereas the scope includes identification of vaginal
infections as an outcome measure. In Bornstein et al. [21],
six out of 34 women in the study group had a false positive
Vision ALD result. Of these, four were diagnosed with
bacterial vaginosis and the other two developed clinically
identifiable PROM within hours of the initial examination.
In the negative diagnosis group, two out of 27 women with
no suspicion of ruptured membranes had a positive Vision
ALD result but were subsequently identified as having
ruptured membranes. In Bornstein et al. [22], 23 out of 309
women initially had a false positive Vision ALD result. Of
these, four were rediagnosed as positive using another
comparator test within 48 h.
The sponsor used an inappropriate appraisal tool,
intended for randomised controlled trials, for reporting the
quality of the included studies. The EAC used the QUA-
DAS tool (QUality Assessment tool for Diagnostic
Accuracy Studies) [24] to appraise the three diagnostic
accuracy studies and rated them as good quality. Overall,
the clinical evidence is good in terms of study design, but
low in volume and only includes comparative diagnostic
accuracy studies. It therefore provides little information
about patient outcomes where clinical decision-making is
based on Vision ALD readings. It is also unable to
demonstrate whether Vision ALD is superior to the
comparator.
4.3 Additional Work Carried Out by the External
Assessment Centre (EAC)
The authors of the two of the Bornstein et al. studies [21,
22] provided the EAC with their study data upon request.
With this the EAC was able to recalculate the diagnostic
accuracy of Vision ALD using the intervention (Vision
ALD assessed by a healthcare professional) and compara-
tor (speculum alone) specified in the scope and to account
for the re-classification of vaginal infections as true
positives.
The diagnostic accuracy of Vision ALD was determined
by the EAC using three different models:
1. Primary analysis: Intervention—clinician reading of
Vision ALD. Comparator—initial clinical diagnosis
using only speculum examination.
2. Post-hoc analysis: As for primary analysis, but women
with initially false positive Vision ALD results who
were later diagnosed with ROM or who gave birth
within 72 h of the study are re-designated as true
positives.
3. Infection as positive analysis: As for the post-hoc
analysis, but false positives due to infections are re-
designated as true positives. This is in accordance with
the NICE scope in which identification of infections is
an outcome measure.
These results are shown in Tables 2 and 3.
Sensitivity, specificity, positive predictive value and
negative predictive value were calculated for each study,
according to the model being used. The comparator was
speculum examination only. Two patients from Bornstein
et al. [22] were excluded from this analysis due to protocol
violations. No patients were excluded from the other
studies. Weighted means for sensitivity, specificity, posi-
tive predictive value and negative predictive values were
used to take into account the sample sizes in the three
studies.
The weighted mean false negative rate (1-sensitivity) for
Vision ALD for the three models varied from 3.2–3.7 %,
which is comparable to that for a speculum examination of
3.9 % [18, 19]. The number of speculum examinations
avoided by using Vision ALD is the number who would be
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sent home following the Vision ALD result. This is derived
from the negative Vision ALD test rate: Bornstein et al. [21]
18/34, Bornstein et al. [22] 131/307 and Mulhair et al. [23]
53/139. The number of patients sent home erroneously fol-
lowing a Vision ALD test is determined from the number of
patients with a false negative Vision ALD result as a pro-
portion of all negative Vision ALD results: Bornstein et al.
[21] 0/34, Bornstein et al. [22] 7/307 and Mulhair et al. [23]
1/139. (This is not the same as the false negative rate, which
is the number of patients with a false negative Vision ALD
result as a proportion of all patients with a positive speculum
result.)
The EAC recalculations show that Vision ALD has high
sensitivity and reasonably high specificity and therefore
shows promise in terms of non-inferiority to the reference
standard. The high sensitivity (97 %) and high negative
predictive value (96 %) means it can reliably rule out
negative cases of PROM and PPROM in the populations
included in these studies. If all women presenting with
unidentified vaginal wetness were initially diagnosed with
Vision ALD and only those with a positive result were then
given a speculum examination, this indicates that around
42 % could avoid this procedure.
4.4 Cost Evidence
The sponsor identified Mulhair et al. [23] as a published
economic study in their economic submission. In this the
authors use their diagnostic accuracy results to speculate
that the use of Vision ALD in the community to rule out
PROM/PPROM could avoid 38 % of such referrals to the
antenatal day unit (ADU) at a cost of £147 each. This is
extrapolated to an approximate annual saving of £33,000
for that unit. However, the EAC considered this was not a
valid economic study of Vision ALD.
The sponsor also provided a de novo economic model
with an NHS perspective. The model structure was shown
in a flow diagram comparing two diagnosis options for
pregnant women with unexpected vaginal wetness who
present at an ADU. The comparator is standard speculum
diagnosis, in which the sponsor included a cardiotocograph
trace (CTG, for detecting foetal heart rate and uterine
Table 2 Diagnostic accuracy parameters recalculated by the External Assessment Centre, by analytic model. PPV positive predictive value,
NPV negative predictive value, CI confidence intervals, for sensitivity, specificity, PPV and NPV these were calculated using Meta-DiSc [25].





PPV % (95 %
CI)




(n = 34) [21]
100.0 (63.1–100.0) 69.2 (48.2–85.7) 50.0 (24.7–75.3) 100.0 (81.5–100.0) 23.5
Bornstein et al.
(n = 307) [22]
95.4 (90.7–98.1) 80.0 (72.8–86.0) 82.4 (75.9–87.7) 94.7 (89.3–97.8) 49.5
Mulhair et al. (n = 139)
[23]
98.3 (90.9–100.0) 65.0 (53.5–75.3) 67.4 (56.5–77.2) 98.1 (89.9–100.0) 42.4
Weighted mean 96.3 (92.9–98.4) 74.3 (68.6–79.5) 75.9 (70.4–80.8) 96.0 (92.3–98.3) 45.6 (32.7–58.6)
Post-hoc
analysis
Bornstein et al. [21] 100.0 (69.2–100.0) 75.0 (53.3–90.2) 62.5 (35.4–84.8) 100.0 (81.5–100.0) 29.4
Bornstein et al. [22] 95.5 (91.0–98.2) 82.1 (75.1–87.9) 84.7 (78.5–89.6) 94.7 (89.3–97.8) 50.8
Mulhair et al. [23] 98.5 (92.1–100.0) 73.2 (61.4–83.1) 77.9 (67.7–86.1) 98.1 (89.9–100.0) 48.9
Weighted mean 96.6 (93.4–98.5) 78.9 (73.2–83.8) 81.3 (76.2–85.7) 96.0 (92.3–98.3) 48.7 (39.1–58.4)
Infection
analysis
Bornstein et al. [21] 100.0 (76.8–100.0) 90.0 (68.3–98.8) 87.5 (61.7–98.4) 100.0 (81.5–100.0) 41.2
Bornstein et al. [22] 95.6 (91.1–98.2) 83.2 (76.2–88.8) 85.8 (79.7–90.6) 94.7 (89.3–97.8) 51.5
Mulhair et al. [23] 98.7 (92.8–100.0) 81.3 (69.5–89.9) 86.0 (76.9–92.6) 98.1 (89.9–100.0) 54.0
Weighted mean 96.8 (93.7–98.6) 83.3 (77.8–87.8) 86.0 (81.3–89.8) 96.0 (92.3–98.3) 51.5 (47.0–55.9)
Table 3 Diagnostic accuracy
parameters (per 1000 initial




Vision patients sent home
erroneously
Bornstein et al. [21] 529 0
Bornstein et al. [22] 427 23
Mulhair et al. [23] 381 7
Weighted mean 421 17
450 A. F. Ray et al.
contractions). In the intervention, Vision ALD is used as
the initial diagnostic test. Patients with a positive Vision
ALD result then go on to have a speculum examination to
confirm membrane rupture (or infection), and a CTG.
Those with a negative result are sent home. The timeframe
for this model was the diagnostic tests only. No treatment
or labour costs or costs associated with infections were
included. The model was presented as a simple Excel
spreadsheet.
The base-case inputs into this model and their sources are
listed in Table 4. For the intervention the model resulted in a
cost of £33.93 per patient. For the comparator, the model
resulted in a cost of £43.94 per patient. Therefore the
potential saving of using Vision ALD from the sponsor’s
model is £10.01 per patient.
The sponsor conducted a one-way sensitivity and
threshold analysis. The cost of the Vision ALD pads and
disposable speculums were fixed, the range for bed day
costs was taken from a published source (not identified)
and other parameters were varied by ±50 %. For the
threshold analysis the sponsor combined the midwife’s
time to conduct a CTG trace and a speculum examination.
Vision ALD remained cost saving over the one-way sen-
sitivity ranges. Threshold analysis indicated that Vision
ALD would no longer be cost saving if the cost of a pad
exceeded £11.60, the time for a midwife to perform a
speculum examination and CTG trace fell below 7.6 min,
the time to administer Vision ALD increased above
12.3 min or the proportion of women with a negative
Vision result fell below 19 %. Multiway analysis indicated
the ‘best case’ (combination of inputs most favourable to
Vision ALD) and ‘worst case’ (least favourable
combination) scenarios for the maximum cost saved and
minimum saved/maximum incurred, respectively, by using
Vision ALD. The best-case scenario produced a cost saving
of £54.60 per patient and the worst-case scenario incurred
an additional cost of £3.52 per patient.
4.5 Critique and Interpretation of Cost Evidence
The sponsor’s de novo cost model was conservative; how-
ever, there were limitations and assumptions that weaken the
model. Table 4 includes the EAC’s comments on the
appropriateness of each input. The EAC conducted a more
detailed sensitivity, threshold and impact analysis and
determined that the cost savings were most sensitive to the
midwife time for a CTG trace, followed by the time to
administer a Vision ALD test and the proportion of patients
with a negative Vision ALD test result. The higher cost of
standard carewas primarily due to the cost ofmidwife time to
undertake the CTG trace. A clinical adviser confirmed that a
CTG trace does not require 20 min of dedicated midwife
time as modelled by the sponsor. The midwife would only
stay to assess the trace if anything adverse is initially
observed. The use of a CTG trace was not included in the
scope, or in the sponsor’s clinical evidence or description of
the clinical pathway. Additionally it could also be used in the
intervention option, during the Vision ALD wear time. The
EAC also considered the cost of a bed day in an ADU (£364
for 24 h) to be very high. The source of this value was unclear
but is based on inpatient bed costs rather than outpatient or
day unit; however, the impact of this is mitigated by the short
stay-time (30–60 min). The sponsor obtained clinical advice
regarding inputs from a single clinician and did not have their
Table 4 Inputs to the sponsor’s base-case economic model. EAC External Assessment Centre, PSSRU Personal Social Services Research Unit,
PROM prelabour rupture of membranes, CTG cardiotocograph, ROM rupture of membranes
Item Value Source EAC comments
Cost of Vision ALD per pad £1.60 Manufacturer Appropriate
Midwife cost per min £1.37 Cost of a nurse in a day ward excluding
qualification costs, PSSRU [27]
Based on Band 5 for qualified nurses. This is low
for midwives (Band 5–8)
Cost of a sterile disposable
speculum
£0.84 Oncall Medical Supplies [28] Appropriate
Cost of a bed day (24 h) in an
antenatal day unit
£364 Reference cost for antenatal false labour
including PROM excess bed day
This should be cost per attendance and cannot be
equated to a bed-day. Source is unknown
Time for midwife to undertake a
CTG trace
20 min Clinical advice Only requires midwife time during set-up and
reading, not the full 20 min trace time
Time for midwife to undertake a
speculum exam
5 min Clinical advice Appropriate
Time spent laying on bed before
speculum
30 min Clinical advice Clinical advisers indicate this can be\60 min,
therefore appropriate
Time to administer Vision 5 min Clinical advice Appropriate
Percentage of patients with
negative ROM following Vision
42 % Published study [23] This is the prevalence rate. It should be the Vision
ALD negative test rate of 38 % from the same
study
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model checked by clinical advisers. The sponsor’s model
does not account for false negative Vision ALD test results
nor for any costs relating to the identification or treatment of
infections as included in the scope.
The NICE scope states that Vision ALD can be
administered in the community (primary healthcare) set-
ting, which was not explored in the sponsor’s model. In
light of this, NICE requested that the EAC model addi-
tional scenarios and inputs, including community use.
4.6 EAC Revisions to the Sponsor’s Economic
Model
The EAC’s revisions to the economic model are separated
into PROM and PPROM models, as the two conditions
vary considerably in treatment, infection rates and costs.
Subgroup analysis in Mulhair et al. [23] indicates that
Vision ALD diagnostic accuracy is not different between
these populations. In standard diagnosis, the speculum
examination can be performed at an ADU, by a general
practitioner (GP) or a midwife at the GP practice. In the
intervention arm, Vision ALD can be administered in these
same settings, or additionally by a midwife visiting the
patient’s home. A positive Vision ALD result is followed
up with a speculum examination, as in the sponsor’s model.
The EAC’s model includes infection, with and without
ROM, as a diagnostic outcome, and the timeframe includes
infection treatment but not labour. The decision tree for
PROM is shown in Fig. 1.
Base-case inputs attached to the model are given in
Table 5. All inputs and the model structure were checked
by clinical advisers. The positive speculum and Vision
ALD result rates were determined as weighted means from
the three clinical studies in the clinical evidence. We used
the EAC post-hoc analysis to determine the rates for the
speculum examination because this model provides the
most complete estimate of the underlying prevalence rate.
We used published infection rates rather than those from
the clinical studies as infection testing was not universally
conducted. We used the post-hoc plus infection analysis for
the PPV for Vision ALD (86 %) as infection was included
as an outcome. False positive results for the speculum
examination are not accounted for as the PPV for this is
very high (97 or 100 % [19]). The EAC model excluded
Vision ALD false negative results because: (1) it has a very
high negative predictive value, and (2) the false negative
rates for Vision ALD and for standard diagnosis (speculum
examination) are very similar. Thus any cost differences
for these patients between the two arms of the model would
be negligible.
There is no evidence or claim that Vision ALD
increases the rate of diagnosis of ROM. The proportion
of patients at each payoff should therefore remain con-
stant, irrespective of whether Vision ALD or standard
diagnosis is used. In practice there were small (\0.8 %)
differences in the patient distributions that were consid-
ered to be due to rounding errors and to the assumption
that the post-hoc analysis represents the true prevalence
rate for ROM. Although we modelled treatment costs,
these were not influential in the cost-consequence anal-
ysis due to these very small differences between out-
come prevalences and are not shown here for simplicity.
Infection rates were similarly unimportant in the cost
differences between diagnosis options. Savings from the
introduction of Vision ALD would therefore be realised
if the cost of administering Vision ALD to all patients is
offset by the savings from the number of speculum
examinations avoided.
Fig. 1 Decision tree for the External Assessment Centre’s revision to the economic model. Figures in italics are probabilities—shown for
prelabour rupture of membrane (PROM). The figure was originally a TIFF file created using the TreeAge Pro modelling software
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4.6.1 Results and Sensitivity Analysis from the External
Assessment Centre (EAC)’s Revisions
to the Economic Model
Base-case results are presented in Table 6 as per patient
cost differences: Vision ALD minus standard care. Vision
ALD is cost-incurring when administered in the same
healthcare setting that a patient would attend for a specu-
lum examination. Additional costs range from £1.28 to
£38.28 depending on the clinician administering the tests
and whether the condition is PROM or PPROM. Much
higher treatment costs for PPROM patients meant that the
small differences in outcome prevalences between the
standard and Vision ALD arms of the model were more
significant in this model. This leads to a consistent addi-
tional £5.75 cost for the Vision ALD arm as seen in the
more positive values for PPROM in Table 6. Vision ALD
was determined to be cost-saving only when it is admin-
istered at a lower clinician cost (for example, by a midwife
at the GP practice or the patient’s home) when the patient
would otherwise have gone to a high-cost scenario for a
speculum examination (GP or ADU). One-way sensitivity
analysis shows that clinician time is the most significant
cost in the model in both PROM and PPROM, which
supports the conclusions of the base-case analysis.
5 NICE Guidance
5.1 Preliminary Guidance
The NICE MTAC met in February 2013 and considered
evidence from a range of sources, including the sponsor’s
submission, the EAC report and additional economic
Table 5 Resources used in the
External Assessment Centre’s
revisions to the economic
model. PPV positive predictive
value, PROM prelabour rupture
of membranes, PPROM
premature prelabour rupture of
membranes, ADU antenatal day
unit, GP general practitioner,
PSSRU Personal Social Services
Research Unit
Item Value Source
Positive speculum result 48.8 % Clinical evidence
Positive Vision result 57.9 % Clinical evidence
Vision false positive rate (1-PPV) 14 % Clinical evidence
Infection rate in women with PROM 1.0 % [11]
Infection rate in women with PPROM 28 % [29]
Infection rate in women without PROM 0.5 % [11]
Time to administer Vision in clinical setting 10 min Clinical advice
Time to administer Vision in patient’s home 15 min Clinical advice
Time for speculum exam 15 min Clinical advice
GP cost per minute £3.68 PSSRU [27]
Midwife at GP surgery, cost per min £0.88 PSSRU [27]
Midwife at patient’s home, cost per min £1.18 PSSRU [27]
Referral cost for an ADU £81.00 NHS Reference Costs, NZ05C [30]
Cost of Vision ALD per pad £1.60 Sponsor
Cost of a sterile disposable speculum £0.84 NHS Supply Chain
Table 6 Base-case cost analysis of Vision ALD administration in different healthcare settings. Positive numbers represent a per-patient cost
incurred by the Vision ALD arm of the model, rows in bold indicate scenarios where Vision ALD is cost saving. PROM prelabour rupture of
membranes, PPROM premature prelabour rupture of membranes, GP general practitioner, ADU antenatal day unit
Vision ALD arm Standard care arm (speculum only) PROM PPROM
Initial Vision ALD test Speculum follow-up
GP GP GP £14.85 £20.60
Midwife at GP Midwife at GP Midwife at GP £4.52 £10.28
Midwife at home Midwife at GP Midwife at GP £7.52 £13.28
ADU ADU ADU £1.28 £7.03
GP Midwife at GP Midwife at GP £32.52 £38.28
GP ADU ADU £3.99 £9.75
Midwife at GP GP GP 2£13.15 2£7.40
Midwife at GP ADU ADU 2£24.01 2£18.25
Midwife at home GP GP 2£10.15 2£4.40
Midwife at home ADU ADU 2£21.01 2£15.25
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modelling, and testimony from clinical experts. The
Committee provisionally decided that:
1. ‘‘The case for adopting the Vision Amniotic Leak
Detector (ALD), when issued by a midwife or other
healthcare worker, is supported by the evidence. The
available evidence suggests that the device can reliably
exclude amniotic fluid leak as a cause of vaginal
wetness in pregnancy, avoiding the need for a specu-
lum examination. Using the device in the community
can prevent unnecessary referrals to secondary care
antenatal day units or maternity triage services for
speculum examinations, releasing clinical time.
2. The Vision ALD should be considered for use in
pregnant women with unexplained vaginal wetness.
3. Based on cost modelling, the use of the Vision ALD is
estimated to be cost saving in scenarios considered to
be clinically likely. When issued by a midwife or other
healthcare worker in a primary-care setting, cost
savings per woman of up to £24.01 (for prelabour
rupture of membranes; PROM) and £18.25 (for
premature prelabour rupture of membranes; PPROM)
could be achieved, through avoiding the need for
referral to an antenatal day unit. When issued by a
community midwife in a woman’s home, Vision ALD
is associated with an estimated cost saving of up to
£21.01 per woman for PROM and £15.25 per woman
for PPROM’’.
The Committee heard advice from clinical experts indi-
cating that in the community settingVisionALDwouldmost
likely be administered by a practice-based or community
midwife, followed by a speculumexamination in anADU for
positive results. In these scenarios, the EAC determined that
Vision ALD would be cost saving. Expert clinical advice
also highlighted that Vision ALD could be issued by a
healthcare worker at a GP practice, and that women con-
tacting an ADU by telephone could be advised to contact a
community or primary care based midwife for administra-
tion of Vision ALD. The use of Vision ALD in an ADU
would be cost-neutral if the consumable costs for the Vision
ALD pad and speculum were included in the referral costs
[30]. The Committee concluded that a change in practice to
avoid secondary care referrals would be acceptable to clin-
icians in the care pathway, and that Vision ALDwould allow
patients to avoid inconvenient, invasive and unnecessary
speculum examinations.
5.2 Consultation Response
The preliminary guidance was available for comment on
the NICE website as a public consultation document
between 22 March and 19 April 2013. Few responses were
received and only one comment from the sponsor resulted
in a minor change to Recommendation 1.1. This was
altered to include reference to the patient benefit of
avoiding the discomfort associated with a speculum
examination. NICE Medical Technology Guidance on
Vision ALD to assess unexplained vaginal wetness in
pregnancy was published on 17 July 2013 as MTG15 [8].
6 Key Challenges and Learning Points
6.1 Original Sources for Parameter Values Should
be Checked
It is easy for errors to perpetuate through the published
literature by citation when articles are not checked
thoroughly. In attempting to verify the sponsor’s quoted
false negative rate for speculum examination, the EAC
located an original reference [18]. It was only by close
examination of this short paper that it was realised that
the rate was being quoted incorrectly. The patient pop-
ulation in Ladfors et al. [18] (women with equivocal
ROM on speculum examination) was subtly different to
that in the scope for Vision ALD and therefore their
results required re-interpretation rather than quoting. The
EAC was able to recalculate the appropriate parameter
which improved the diagnostic performance of the
comparator in the evaluation of Vision ALD [19].
6.2 Diagnostic Accuracy Studies Should be
Supplemented by Implementation Studies
Comparative studies between a novel diagnostic interven-
tion and a ‘gold standard’ reference comparator, such as
those included in this assessment, can only demonstrate
non-inferiority of the intervention. The sensitivity of
Vision ALD for the diagnosis of ROM is very high and
comparable to that for speculum examination. Only a
controlled trial that implements treatment decisions based
on the results of Vision ALD could demonstrate superiority
over the current NHS standard diagnosis. It would also
provide additional data for economic modelling and may
help to encourage adoption, especially in such cases as this
where changes in the patient pathway are necessary in
order to realise cost-savings.
6.3 Implementation can be Key to the Realisation
of Cost Savings for Medical Devices
In the case of Vision ALD, nearly half of women pre-
senting with unexplained vaginal wetness could avoid an
unnecessary speculum examination, which some women
may find uncomfortable or embarrassing. However, by
implementing Vision ALD in the same setting as current
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standard diagnosis the savings from avoided referrals did
not outweigh the cost of additional Vision ALD tests. Cost
savings were only realisable if the care pathway was
altered so that the initial testing could be conducted by a
lower cost healthcare professional. This is possible because
speculum examinations require skilled nursing or medical
staff plus a consulting space, whereas Vision ALD could be
administered (e.g.) at the patient’s home.
Medical devices and diagnostic tests differ significantly
from pharmaceuticals in that the costs and benefits of using
them are dependent on their mode of use. Also, new
healthcare technology in general is likely to increase
healthcare costs [31, 32]. As the emphasis of NICE medical
technologies guidance is to evaluate technologies that
either provide additional benefit at similar cost or are cost
saving compared to current standard care [33], the clinical
pathway into which the technology fits may need to be
altered in order to achieve any financial savings. Manu-
facturers, evaluators and adopters should not be shy of
investigating alternative pathways to identify the greatest
benefit to patients and the healthcare system.
6.4 Treatment Costs were Essentially Irrelevant
to the Cost-Consequences Modelling
A new diagnostic technology may result in earlier detection
of a condition or in the detection of additional cases. In
such cases treatment costs are likely to be increased fol-
lowing implementation. However, in the case of Vision
ALD, no change in the diagnostic outcomes was expected.
Therefore, costs were either saved or incurred solely due to
the diagnostic tests themselves, or the healthcare set-
ting/clinician time used to administer them.
6.5 Clinical Advisers Should Reflect Both
the Current Care Pathway and the Proposed
Care Pathway in a Technology Assessment
Clinical advice was provided to the EAC by secondary-
care professionals, but no representation from primary care
was available. Medical technologies can be cost saving
through disruption of care pathways and by changing the
settings in which care is delivered. Therefore advisers are
needed for both the standard care and proposed new
settings.
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